Clinical Director of Imperial College’s Center for Psychedelic Research Joins Entheon Advisory Board Post published:August 25, 2021 Post category:Press Release
Tryp Therapeutics Completes Psychotherapy Training for Phase 2a Study at the University of Florida Post published:August 24, 2021 Post category:Press Release
Mindset Pharma Broadens its IP Portfolio by Filing U.S. Provisional Patent Extending its DMT and 5-MeO-DMT Inspired Psychedelic Drug Candidates Post published:August 24, 2021 Post category:Press Release
CB Therapeutics Expands Biomanufacturing IP Portfolio Post published:August 24, 2021 Post category:Press Release
MindMed Announces Collaboration With Forian To Advance Development Of Personalized Psychiatry For Anxiety Disorders Post published:August 24, 2021 Post category:Press Release
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan Post published:August 24, 2021 Post category:Press Release
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs Post published:August 19, 2021 Post category:Press Release
Wesana Health Highlights Recent Appointments to Board of Directors Post published:August 19, 2021 Post category:Press Release
Tryp Therapeutics Appoints Dennis Langer, M.D., J.D. as Senior Advisor Post published:August 18, 2021 Post category:Press Release
Bright Minds Biosciences (“BMB”) Proprietary 5-HT2C Agonist Shows Significant Reduction in Seizure Activity Post published:August 18, 2021 Post category:Press Release